2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178191
    SGC stimulator 1 98%
    sGC stimulator 1 is a carbonyl sulfide (COS)/H2S-donor hybrid soluble guanylyl cyclase (sGC) stimulator (EC50 = 496 nM). sGC stimulator 1 exhibits a well-characterized H2S-releasing property. sGC stimulator 1 reduces fibrosis in TGF-β1-treated cardiac fibroblasts by increasing cGMP and H2S levels. sGC stimulator 1 can exert anti-fibrotic effects by activating sGC and increasing H2S. sGC stimulator 1 can be used for the study of heart failure (HF).
    SGC stimulator 1
  • HY-178319
    Photoazolol-1 2482779-07-5
    Photoazolol-1 is a β-adrenergic receptor (βAR)-blocker derivative. Photoazolol-1 can transfer from an inverse agonist to a neutral antagonist upon photoactivation.
    Photoazolol-1
  • HY-178332
    sEH/PPARδ modulator 1
    sEH/PPARδ modulator 1 is a sEH/PPARδ dual modulator. sEH/PPARδ modulator 1 can inhibit sEH with an IC50 of 0.46 μM and activate PPARδ with an EC50 of 0.12 μM. sEH/PPARδ modulator 1 can be used for the researches of inflammation, metabolic and cardiovascular disease.
    sEH/PPARδ modulator 1
  • HY-178344
    Multi-target kinase-IN-6
    Multi-target kinase-IN-6 is a Multiple target kinase inhibitor. Multi-target kinase-IN-6 can inhibit cardiac RyR2- and NaV1.5-channels but stimulate SERCA2a pump activity. Multi-target kinase-IN-6 can be used for the research of cardiovascular disease, such as heart failure.
    Multi-target kinase-IN-6
  • HY-178434
    BRP-821
    BRP-821 is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.4 nM. BRP-821 can be used for the researches of inflammation, cardiovascular, metabolic and neurological disease .
    BRP-821
  • HY-178486
    SH6
    SH6 is a transcription factor ZBTB7A degrader. SH6 is promising for research of β-hemoglobinopathies such as sickle cell disease (SCD) and β-thalassemia.
    SH6
  • HY-178509
    TRPV4-KCa2.3 modulator 1 2616611-60-8
    TRPV4-KCa2.3 modulator 1 (Compound IB-2) is a TRPV4-KCa2.3 protein complex enhancer with antihypertensive activity. TRPV4-KCa2.3 modulator 1 enhances endothelial cell hyperpolarization and vasodilatio. TRPV4-KCa2.3 modulator 1 is promising for research of hypertension and cardiovascular disorders.
    TRPV4-KCa2.3 modulator 1
  • HY-179024
    NP3-742 98%
    NP3-742 is an orally active NLRP3 inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC50s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis.
    NP3-742
  • HY-179065
    VU0494372 882235-30-5
    VU0494372 is an activator of potassium ion channel KCNQ1. VU0494372 can significantly enhance the cell surface expression and transport efficiency of KCNQ1. VU0494372 does not alter KCNQ1 mRNA levels and protein degradation rate, and has no significant cytotoxicity. VU0494372 can be used for research on cardiovascular conditions.
    VU0494372
  • HY-179106
    PCSK9-IN-34 3035306-81-8
    PCSK9-IN-34 is a small molecule PCSK9 inhibitor. PCSK9-IN-34 can be used for research on cardiovascular conditions.
    PCSK9-IN-34
  • HY-179246
    CXT29
    CXT29 is an orally active COX-2 inhibitor and a thromboxane A2 receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC50 values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC50 of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases.
    CXT29
  • HY-18200A
    Atopaxar hydrochloride 474544-83-7 98%
    Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC50 of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC50=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease.
    Atopaxar hydrochloride
  • HY-18200B
    Atopaxar hydrobromide 474550-69-1 98%
    Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease.
    Atopaxar hydrobromide
  • HY-18204R
    Valsartan (Standard) 137862-53-4
    Valsartan (Standard) is the analytical standard of Valsartan. This product is intended for research and analytical applications. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
    Valsartan (Standard)
  • HY-18252R
    Avanafil (Standard) 330784-47-9
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil (Standard)
  • HY-18252S
    Avanafil-13C,d3 2738376-89-9 98%
    Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil.
    Avanafil-13C,d3
  • HY-18600B
    (E)-Azimilide 1294552-65-0 98%
    (E)-Azimilide is an isomer of Azimilide (HY-18600), a class of antiarrhythmic compounds that inhibit I(Ks) and I(Kr) activity.
    (E)-Azimilide
  • HY-18660A
    Ciraparantag TFA 1438492-27-3 98%
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag TFA
  • HY-18660S
    Ciraparantag-d8 (tetra(hydrochloride) diacetate) 98%
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)
  • HY-18732B
    L-NMMA citrate 209913-88-2 98%
    L-NMMA citrate competitively antagonizes L-arginine, and thus inhibits production of nitric oxide (NO). L-NMMA is utilized as NO synthase antagonist in experimental settings.
    L-NMMA citrate
Cat. No. Product Name / Synonyms Application Reactivity